It's September — back-to-school season, cooling temperatures, and for millions of people, the start of the worst time of year for asthma and allergies. You know the pattern: the wheezing that wakes you up at night, the inhaler that never seems far from your hand, the eczema flare-ups that leave your skin red, itchy, and raw. You've tried the standard treatments — inhaled corticosteroids, antihistamines, topical steroids — but for severe, uncontrolled asthma or moderate-to-severe atopic dermatitis, these often aren't enough. Your doctor mentions a biologic medication. You feel hopeful — until you see the price tag.
Asthma affects approximately 25 million Americans, and allergic diseases impact over 50 million. In Europe, an estimated 150 million people suffer from allergic conditions. September is particularly notorious — epidemiologists even call it the "September asthma epidemic," as children return to school, viral infections spread, and ragweed pollen peaks across much of the US and Europe. For patients with severe, uncontrolled asthma — those who experience frequent exacerbations, emergency room visits, and hospitalizations despite standard inhaler therapy — biologic medications have been transformative. These targeted therapies, which block specific inflammatory pathways in the immune system, can dramatically reduce asthma attacks, improve lung function, and enhance quality of life.
Similarly, for patients with moderate-to-severe atopic dermatitis (eczema) — a chronic inflammatory skin condition characterized by intense itching, redness, and skin lesions that can disrupt sleep, work, and daily life — biologic therapies have revolutionized treatment, offering long-term control that topical steroids and older systemic medications often cannot achieve.
But these medications come with staggering price tags. In the United States, Dupixent (dupilumab) — one of the most widely prescribed biologics for both severe asthma and atopic dermatitis — has a list price of $4,193 per carton (containing two 300mg injections), with retail prices typically ranging from $4,000 to $5,500 per carton depending on the pharmacy. At the standard dosing of one carton every two weeks, that translates to approximately $109,000 per year at list price — and even with insurance, specialty tier co-pays, prior authorization hurdles, and coverage gaps can leave patients paying thousands of dollars out of pocket annually. For the uninsured or underinsured, these medications are simply out of reach.
It's no wonder, then, that a growing number of patients with severe asthma and atopic dermatitis are looking beyond their borders for treatment. And increasingly, they're discovering that **medical treatment in China** offers access to the same biologic medications — plus comprehensive allergy and immunology care — at a fraction of the cost.
When people think about **affordable surgery abroad**, asthma and eczema might not be the first things that come to mind. But China has developed sophisticated allergy and immunology programs — with particular expertise in biologic therapy for severe asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and other allergic conditions — and international patients are starting to take notice.
**Dramatic cost savings.** This is where the numbers really speak. Dupixent (dupilumab) in China costs approximately ¥3,260 (about $450) per carton of two 300mg injections — compared to $4,193 to $5,500 per carton in the United States. At the standard dosing of one carton every two weeks, annual treatment in China costs approximately $11,700 — versus $109,000 or more at US list prices. That's savings of approximately 80 to 89 percent. Even after factoring in flights, accommodation, and a companion's expenses, the total cost for an initial evaluation and several months of biologic therapy in China is often dramatically lower than what you'd pay out-of-pocket at home for just a month or two of medication. For patients facing a lifetime of biologic therapy, these savings can be truly transformative.
**The same medications, a fraction of the price.** China's leading allergy and immunology centers offer the same international biologic brands used in Western centers — all approved by China's NMPA (National Medical Products Administration). These include:
- **Dupilumab (Dupixent)** — for moderate-to-severe atopic dermatitis, severe eosinophilic or oral-steroid-dependent asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis
- **Omalizumab (Xolair)** — for severe persistent allergic asthma and chronic spontaneous urticaria
The difference isn't the medication — it's the price, driven by China's national volume-based procurement (VBP) reforms, negotiated pricing with pharmaceutical manufacturers, and a lower-cost healthcare system. Patients receive the identical medication, manufactured by the same companies, at a significantly lower cost.
**Comprehensive allergy and immunology evaluation.** Effective biologic therapy begins with a precise diagnosis and phenotyping. China's leading allergy and immunology centers offer comprehensive evaluation, including detailed allergy testing (skin prick testing, specific IgE blood tests, component-resolved diagnostics), pulmonary function testing with bronchodilator response, FeNO (fractional exhaled nitric oxide) testing, eosinophil counts, and total IgE levels. This thorough phenotyping ensures that patients are matched with the most appropriate biologic therapy for their specific asthma or eczema phenotype — whether eosinophilic, allergic, or another subtype. For international patients, this comprehensive evaluation provides clarity and confidence that their treatment plan is tailored to their individual needs.
**Multidisciplinary care.** Severe asthma and atopic dermatitis often coexist with other allergic conditions — allergic rhinitis, food allergies, chronic sinusitis, and eosinophilic esophagitis. China's leading allergy and immunology centers offer multidisciplinary clinics that bring together allergists, pulmonologists, dermatologists, ENT specialists, and gastroenterologists to provide holistic, coordinated care. This team-based approach ensures that all aspects of a patient's allergic disease are addressed in a single treatment plan. For international patients, this coordinated model means fewer trips, less confusion, and more consistent care.
**High volume = deep expertise.** In allergy and immunology, as in many medical fields, experience matters. China's top allergy and immunology departments handle enormous patient volumes — some of the largest in the world. Allergists and immunologists at these centers manage thousands of patients with severe asthma, atopic dermatitis, and complex allergic conditions every year, developing deep expertise in biologic therapy selection, dosing optimization, and management of treatment-resistant cases. For patients, this depth of experience translates into personalized, evidence-based treatment plans and reliable outcomes.
**Why are prices so much lower?** China's national volume-based procurement (VBP) program — which leverages the purchasing power of the world's largest healthcare system to negotiate dramatically lower drug prices — has driven down the cost of biologic medications significantly. Combined with negotiated pricing with international pharmaceutical manufacturers (who often offer lower prices in the Chinese market to gain access to its vast patient population), lower operational costs, and efficient hospital workflows, these savings are passed directly to patients — without compromising on medication quality or regulatory standards.
**International standards of care.** Many **Chinese hospitals for international patients** have allergy and immunology departments at Grade 3A hospitals — China's highest hospital classification. These facilities adhere to international infection control protocols, use NMPA-approved (and often FDA- or EMA-approved) medications, and follow global best practices for asthma and allergy management and patient safety. For patients considering long-term biologic therapy — where medication quality, proper storage, and careful monitoring are critical — these standards provide peace of mind that the care they receive meets the highest global benchmarks.
If you're considering biologic therapy abroad, you probably have questions about the process. How does the evaluation work? What about ongoing medication and follow-up? Is there a language barrier?
Many top Chinese allergy and immunology centers offer comprehensive international patient services, including:
- Remote initial consultations based on your existing medical records, pulmonary function tests, and lab results
- Comprehensive pre-treatment evaluation, including allergy testing, pulmonary function testing, FeNO, and blood work
For patients who want support from the very beginning, services like **CNHealthLink** specialize in connecting international patients with China's leading allergy and immunology centers. From initial case evaluation through treatment and follow-up, these platforms help patients navigate the process of seeking **medical treatment in China** — ensuring they have the information and support they need at every step of their care journey.
Of course, **affordable surgery abroad** and biologic therapy in China isn't the right choice for everyone. Severe asthma and atopic dermatitis are chronic, lifelong conditions that require ongoing monitoring — patients should have a plan for long-term follow-up and medication management with a healthcare provider at home after initiating treatment in China. Patients should also be aware that biologic medications require proper storage (refrigeration) and careful handling, and that bringing medications across international borders may be subject to customs regulations. An acute asthma attack is a medical emergency that requires immediate local treatment — it cannot wait for international travel. And as with any medication, biologics carry potential risks and side effects — including injection site reactions and, in some cases, increased susceptibility to certain infections — that should be discussed thoroughly with your care team.
But for patients with severe, uncontrolled asthma or moderate-to-severe atopic dermatitis who are struggling to afford their biologic medication — those facing high co-pays, prior authorization denials, or the prospect of going without treatment entirely — exploring biologic therapy in China could be well worth considering. The combination of the same NMPA-approved biologic medications used in Western centers, comprehensive allergy and immunology evaluation, multidisciplinary care, high specialist volumes, and dramatic cost savings makes China an increasingly attractive destination for severe asthma and eczema treatment.
If you're living with severe asthma or atopic dermatitis — and the cost of your medication is adding stress to an already challenging condition — know that you have options. Research accredited facilities, compare costs and treatment options, and consider reaching out to a medical advisory service that specializes in international allergy and immunology care. They can help you understand whether biologic therapy in China might be right for your specific condition.
You don't have to let severe asthma or eczema control your life — and you don't have to pay a fortune for the treatment that could change it. Sometimes, the path to affordable, effective relief leads further than you think.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making decisions about treatment. An acute asthma attack is a medical emergency requiring immediate local care. Severe asthma and atopic dermatitis require lifelong monitoring; treatment outcomes vary by individual and are not guaranteed.